CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: To assess the LSC potential of CD93+ and CD93− stem/progenitor cells in vitro, CFC replating and LTC-IC assays were performed on primary CP-CML samples sorted into Lin−CD34+CD38-CD90+CD93+ (LSC-CD93+) and Lin−CD34+CD38−CD90+CD93− (LSC-CD93−) populations (Fig. S2).